ASX RELEASE 30th August 2022

# Paradigm Appoints Interim Company Secretary

**Paradigm Biopharmaceuticals Ltd (ASX: PAR) ("Paradigm" or "the Company"),** a late-stage drug development company wishes to advise the passing of its long-term Company Secretary Kevin Hollingsworth who had been with Paradigm since its original ASX listing. Paradigm wishes to acknowledge Kevin's contribution and passion for Paradigm – and expresses its sincere condolences to the Hollingsworth family.

Paradigm also announces it has appointed Ms Abby Macnish as the interim Company Secretary. Abby will be Paradigm's Company Secretary for a period of 9 -12 months or until a full-time appointment is made. Abby is an investment professional with over 15 years' experience. Currently, Abby works closely with the Executive Chair at McRae Investments, analysing transactions, managing investments and monitoring cash flows and financials. She is the CFO and Company Secretary for two ASX listed companies, and Non-executive Director of several unlisted Australian companies in the Biotech and Wealth Management fields. Abby is also the Chair of the Investment Committee at TWD Australia and a board member for Muscular Dystrophy WA (MDWA), a charity with the aim of supporting the MDWA community. She has a Bachelors' Degree in Science and Commerce from the University of Western Australia and is a Chartered Financial Analyst® (CFA) charter-holder.

## About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals LTD (ASX: PAR) is a late-stage drug development company with the mission to develop and commercialise Pentosan Polysulfate Sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection or genetic predisposition. Paradigm is also exploring proof-of-concept studies for the use of PPS in respiratory and heart failure indications.

Authorised for release by the Paradigm Board of Directors.

To learn more please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:
Simon White
Director of Investor Relations
Tel: +61 404 216 467
Paradigm Biopharmaceuticals Ltd
ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
Email: investorrelations@paradigmbiopharma.com